dipyridamole has been researched along with Rupture in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Rupture: Forcible or traumatic tear or break of an organ or other soft part of the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benzimra, JD | 1 |
| Johnston, RL | 1 |
| Jaycock, P | 1 |
| Galloway, PH | 1 |
| Lambert, G | 1 |
| Chung, AK | 1 |
| Eke, T | 1 |
| Sparrow, JM | 1 |
1 other study available for dipyridamole and Rupture
| Article | Year |
|---|---|
The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications.
Topics: Aged; Anesthetics, Local; Anticoagulants; Aspirin; Blood Loss, Surgical; Cataract Extraction; Choroi | 2009 |